MyOme Adds Sam Roosz and Dr. Ravi Thadhani to Board of Directors

MyOme has appointed Sam Roosz and Dr. Ravi Thadhani to its Board of Directors, announced in a press release. The company said the appointments strengthen its leadership as it expands its AI powered whole genome healthcare platform.

Sam Roosz is the Co-Founder and CEO of Crescendo Health and previously Co-Founder of Datavant. His experience includes building large-scale health data ecosystems and forming enterprise partnerships that connect providers, researchers, and public agencies. At MyOme, he will guide efforts to scale genomic solutions across health systems, life sciences, employers, and population health networks.

Dr. Ravi Thadhani serves as Executive Vice President of Clinical Affairs and Chief Medical Officer at Cedars-Sinai. He brings more than three decades of experience in academic medicine and regulatory strategy, having held leadership roles at Emory University, Harvard Medical School, and Mass General Brigham. His background includes oversight of data safety monitoring and navigating diagnostics through FDA approval pathways.

MyOme’s platform uses AI and integrated risk modeling to deliver genomic insights across clinical care and research applications, including cardiometabolic, liver, kidney, cognitive disease, oncology, rare conditions, and pharmacogenomics.